Literature DB >> 12509966

Epidermal growth factor receptor expression in ameloblastoma.

Marilena Vered1, Izhar Shohat, Amos Buchner.   

Abstract

UNLABELLED: Ameloblastoma is a locally aggressive tumor with possible lethal potential. Currently extensive surgery is the most acceptable treatment modality. AIM: To investigate the presence of EGFR in ameloblastoma in order to consider using newly developed anti-EGFR therapeutic agents in cases of unresectable tumors. The study consisted of 58 formalin-fixed, paraffin-embedded specimens of ameloblastoma that were immunohistochemically stained with a monoclonal anti-EGFR antibody (clone 31G7). Positive and negative controls determined specificity of the antibody. A staining score based on the staining intensity and the proportion of stained cells was established, ranging between 0 and 2. All specimens were EGFR positive; 8 (14%) exhibited the maximum score of 2 and 19 (33%) scored between 1 and 2. Since ameloblastomas are EGFR-positive tumors, anti-EGFR agents could be considered to reduce the size of large tumors and to treat unresectable tumors that are in close proximity to vital structures. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509966     DOI: 10.1016/s1368-8375(02)00034-9

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  10 in total

1.  EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence.

Authors:  Azza Abdel-Aziz; Maha M Amin
Journal:  Diagn Pathol       Date:  2012-02-02       Impact factor: 2.644

2.  Immunohistochemical evaluation of podoplanin in odontogenic tumours & cysts using anti-human podoplanin antibody.

Authors:  Namrata Singhal; Nitin Khanduri; Deepak Kurup; Brijesh Gupta; Pranjan Mitra; Roshani Chawla
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-17

3.  Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature.

Authors:  Mounia Amzerin; Zouhour Fadoukhair; Rhizlane Belbaraka; Meryem Iraqui; Saber Boutayeb; Hind M'rabti; Tayeb Kebdani; Khaled Hassouni; Najib Benjaafar; Brahim K El Gueddari; Hassan Errihani
Journal:  J Med Case Rep       Date:  2011-10-03

4.  Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis.

Authors:  Hope M Amm; Mary MacDougall
Journal:  Curr Oral Health Rep       Date:  2016-03-31

5.  Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas.

Authors:  Núbia Braga Pereira; Ana Carolina de Melo do Carmo; Marina Gonçalves Diniz; Ricardo Santiago Gomez; Dawidson Assis Gomes; Carolina Cavalieri Gomes
Journal:  Oncotarget       Date:  2015

Review 6.  Histatin peptides: Pharmacological functions and their applications in dentistry.

Authors:  Zohaib Khurshid; Shariq Najeeb; Maria Mali; Syed Faraz Moin; Syed Qasim Raza; Sana Zohaib; Farshid Sefat; Muhammad Sohail Zafar
Journal:  Saudi Pharm J       Date:  2016-05-04       Impact factor: 4.330

7.  MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report.

Authors:  Danyang Li; Shuning Xu; Miaomiao Sun; Lei Qiao; Lifeng Wang; Ying Liu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

8.  Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts.

Authors:  Marieh Honarmand; Shirin Saravani; Nazanin Kamyab; Mehdi Jahantigh; Molouk Torabi Parizi
Journal:  Iran Red Crescent Med J       Date:  2015-11-06       Impact factor: 0.611

9.  High frequency of BRAF V600E mutations in ameloblastoma.

Authors:  Kari J Kurppa; Javier Catón; Peter R Morgan; Ari Ristimäki; Blandine Ruhin; Jari Kellokoski; Klaus Elenius; Kristiina Heikinheimo
Journal:  J Pathol       Date:  2014-01-31       Impact factor: 7.996

10.  Metastasizing Maxillary Ameloblastoma: Report of a Case with Molecular Characterization.

Authors:  Matteo Rotellini; Giandomenico Maggiore; Massimo Trovati; Massimo Squadrelli Saraceno; Alessandro Franchi
Journal:  J Oral Maxillofac Res       Date:  2016-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.